Page 1

Supplementary Information

Terpyridine-Cu(II) Targeting Human Telomeric DNA to Produce Highly Stereospecific G-quadruplex DNA Metalloenzyme

Yinghao Li,^{ab} Mingpan Cheng,^{ab} Jingya Hao,^{ab} Changhao Wang,^a Guoqing Jia*^a and Can Li*^a

^aState Key Laboratory of Catalysis, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China. ^bUniversity of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing, 100049, China.

*E-mail: canli@dicp.ac.cn; gqjia@dicp.ac.cn.

Content

Supplementary Results	3
Supplementary Methods	12
General Methods	12
Supplementary Methods Note 1: Synthesis of substrates and racemic products	15
Supplementary Methods Note 2: Synthesis of ligands and metal complexes	15
Supplementary Methods Note 3: General catalytic procedure	19
Supplementary Methods Note 4: HPLC analysis condition	20
Supplementary Methods Note 5: Calculation the conversion of 1a	20
Supplementary Methods Note 6: Kinetic measurements	21
¹ H and ¹³ C NMR Spectra of Products	22
HPLC Traces of Products	
References	60

Supplementary Results

Fig. S1 Catalytic activity of HT G4-DNA metalloenzymes for the Diels-Alder reaction of **1a** and **2** at pH 6.5. Smooth curve shows the fit to the Michaelis–Menten equation.



^{*a*} Enzymatic kinetic parameters (k_{cat} and K_M) were obtained by fitting the kinetic data to the Michaelis–Menten equation ($v_0 = k_{cat}[E_{catalyst}]_0[S_{1a}]_0/(K_M + [S_{1a}]_0))$). k_{cat}/K_M values were obtained by fitting the linear portion of the Michaelis–Menten plot to $v_0 = (k_{cat}/K_M)[E_{catalyst}]_0[S_{1a}]_0$. N.D., not determined.

Page 4



Fig. S2 Isothermal titration calorimetry (ITC) profile of different cofactors (CuLn) binding to human telomeric G-quadruplex DNA (HT21) in 30 mM NH₄Cl at 298K. Data were fitted to "two-event" (CuL1-L4) or "one-event" (CuL5) binding model using Origin 8.0 software.



Fig. S3 Comparison of the thermodynamic signature of different cofactors (CuLn) binding to human telomeric G-quadruplex DNA (HT21) in 30 mM NH₄Cl at 298K.



Fig. S4 Normalized melting curves of HT G4-DNA metalloenzymes with different terpyridine-Cu(II) cofactors as compared with HT21 itself in NH_{4^+} media monitored by UV absorption at 295 nm (DNA strand concentration, 5 μ M; NH₄Cl, 30 mM; CuLn, 10 μ M; MOPS buffer, 20 mM, pH 6.5).



Fig. S5 CD spectra of derivative HT G4-DNA metalloenzymes with flanking bases at 5'-end (a-c) or 3'-end (d-f) (DNA strand concentration, 5μ M; NH₄Cl, 30 mM; CuL1, 10 μ M; MOPS buffer, 20 mM, pH 6.5).

The stability of HT21-NH4⁺-CuL1 is evaluated by recycling experiment (Fig. S6). After every reaction, the products were extracted with ether and fresh substrates were added into the aqueous phase containing HT21-NH₄⁺-CuL1 catalyst. The results of recycling show that there are some degree of decrease in catalytic activity and enantioselectivity for G-quadruplex DNA metalloenzyme (Fig. S6a). This might be due to the structural change of G-quadruplex DNA metalloenzyme as indicated in CD spectra (Fig. S6b).



Fig. S6 Recycling experiments for evaluating the stability of HT21-NH₄⁺-CuL1. (a) Catalytic results. (b) CD spectra of HT21-NH₄⁺-CuL1 when fresh preparing or after 5^{th} round catalysis.

We have used 2 equivalents of CuL1 compared to HT21 because the maximum enantiomeric excess (ee) can be obtained there.

As shown in Fig. S7a, the plot of the initial rate (v_0) as a function of [CuL1]:[HT21] shows that the activity increases dramatically until a molar ratio of 1:1 is reached, after which no significant increase can be observed. This indicates that a high active site has been formed at a molar ratio of 1:1.

However, a moderate enantioselectivity together with a big error bar is observed for the molar ratio of 1:1 (Fig. S7b). Until the ratio of [CuL1]:[HT21] increases to 2, the enantioselectivity reaches the maximum with negligible error bar. CD spectroscopic study further indicates that there is a great structural change of HT21 upon addition of 1 equivalent of CuL1 (Fig. S7c). Subsequently, a relatively stable structure is formed beginning with the molar ratio of 2. In combination with enantioselectivity and CD data, we deduce that the stable HT21 G-quadruplex DNA stabilized by 2 or more CuL1 is necessary for a highly specific enantioselectivity. In addition, ITC data tell us there are two binding events of CuL1 within HT21 G-quadruplex DNA, one is high-affinity and the other is low-affinity (Table 3). Therefore, we think that the first CuL1 with high-affinity is main active site and the second CuL1 with low-affinity mainly plays a structural role in constructing and stabilizing a catalytic 3D structure.



Fig. S7 Functional characterization of the catalysts. Plot of the initial rate (v_0) (a) and enantioselectivity (b) of model Diels-Alder reaction as a function of [CuL1]:[HT21] catalyzed by HT21-NH₄⁺-CuL1. (c) CD spectra of different ratio of [CuL1]:[HT21] in 30 mM NH₄⁺.

Binding events	$K_{a}\left(M^{-1} ight)$	n	$\Delta \mathrm{H}^b$	$-T\Delta S^b$	$\Delta \mathbf{G}^{b}$
1 st	(1.5±0.6)E8	1.0	-19.1±3.1	7.9	-11.2
2 nd	(3.2±0.9)E6	5	-4.7±0.3	-4.2	-8.9
3 rd	(3.3±1.5)E7	2	6.2±1.5	-16.3	-10.1

Table S1 Binding thermodynamic parameters of molecular recognition between terpyridine-Cu(II) complex (CuL1) and human telomeric DNA sequence (HT21) at 298K^a

^{*a*} The data were obtained by the three sets of sites model.

^{*b*} Units are kcal•mol⁻¹.

Table S2 Control experiments



^{*a*} Determined for the crude product by HPLC analysis on a chiral stationary phase (**Supplementary Methods Note 5**), Reproducible within $\pm 5\%$. ^{*b*} Determined by chiral-phase HPLC. Reproducible within $\pm 2\%$. Reaction conditions: **1a** (1 mM), **2** (10 uL, 260 mM), human telomeric G-quadruplex DNA (50 μ M), **L1** (100 μ M) or Cu(NO₃)₂ (100 μ M), NH₄Cl

(30 mM), MOPS buffer (20 mM, pH 6.5), 4 $^{\circ}$ C, 24h.

Supplementary Methods

General Methods

Materials: The 21-base human telomeric sequence 5'-d(GGGTTAGGGTTAGGGTTAGGGTTAGGG)-3' (HT21) and its flanking base variants (see details in Table 1) were purchased from Sangon (Shanghai, China). Unnatural L-DNA was obtained from Takara (Dalian, China). The DNA strand concentrations were determined by measuring the UV absorbance of sample at 260 nm by using the molar extinction coefficient values provided by the manufacturer. Cu(NO₃)₂-3H₂O (>99.5%), NaCl (>99.5%), KCl (>99.5%), NH₄Cl (>99.5%) were purchased from the Shanghai Chemical Reagent Company of the Chinese Medicine Group. 3-(N-morpholino)propanesulfonic acid (MOPS) were purchased from Sangon (Shanghai, China). Water purified on a Milli-Q A10 water purification system (specific resistance of 18.2 M Ω at 25 °C) was used for all experiments. All experiments were carried out in 20 mM MOPS buffer (pH 6.5) unless otherwise stated. Ligands (L1-L4) and metal complexes CuLn (L1-L6) were synthesized as described in Supporting Information (see Supplementary Methods Note 2). L5 and L6 were obtained from commercial sources and used without further purification. Dienophiles **1a-f**, **4a-e** and their corresponding racemic products were prepared according to the literature (see **Supplementary Methods Note 1**).

UV Melting Experiment. UV melting experiments were carried out on a Shimadzu 2450 spectrophotometer (Shimadzu, Japan) equipped with a Peltier temperature control accessory. A sealed quartz cell with a path length of 1.0 cm was used. The UV melting curves of the human telomeric G-quadruplexes (5 μ M) and their metalloenzymes were monitored by UV absorption at 295 nm with a heating rate of 0.5 °C/min. Data were analyzed by using Origin 8 software. The

melting temperatures (Tm) can be obtained from the best sigmoidal curve fit of the melting profile.

Circular Dichroism (CD) Spectroscopy. All CD spectra were recorded on a dual beam DSM 1000 CD spectrophotometer (Olis, Bogart, GA) with a 10 mm path-length quartz cell. Each measurement was recorded from 220 to 400 nm at 20 °C under N₂ purge. The scan rate was 0.5 nm per second. The average scan for each sample was subtracted by a background CD spectrum of corresponding buffer solution. CD samples of all G-quadruplexes were prepared at a concentration (G-quadruplex unit) of 5 μ M by using a MOPS buffer (20 mM, pH 6.5) containing corresponding salts (50 mM NaCl or 150 mM KCl or 30 mM NH₄Cl). When binding with CuLn complexes (10 μ M), the CD spectra of corresponding human telomeric G-quadruplex DNA metalloenzymes were recorded then.

High Performance Liquid Chromatography (HPLC). The enantioselectivity was determined by Agilent HPLC 1260 analysis using Daicel chiralcel OD, ODH, OJH or chiralpak AD, ADH column with a UV-detector by using isopropanol and n-hexane as eluents at 25 °C.

¹**H** and ¹³**C** NMR Spectroscopy. All ¹H and ¹³C NMR spectra were recorded on a Bruker-400 MHz NMR instrument in CDCl₃ using TMS or residual protic solvent signals as internal standard. Data for ¹H NMR are recorded as follows: chemical shift (δ , ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet or unresolved, coupling constant(s) in Hz, integration).

Isothermal Titration Calorimetry (ITC). ITC measurements were carried out at 25 °C using a $MicroCal^{TM}$ ITC₂₀₀ titration calorimeter (MicroCal, GE). Experiments were performed in MOPS buffer (20 mM, pH 6.5) containing NH₄Cl (30 mM). The reference cell in the ITC was filled with ultrapure water (18.2 M Ω cm⁻¹ resistivity). A pre-folded human telomeric G-quadruplex

DNA (20 μ M) in NH₄Cl was loaded into the calorimeter cell. Then the syringe was loaded with CuLn complex (1 mM) in corresponding buffers. Following the auto-equilibration and an initial 500 s delay, the CuLn titrant divided into 25 injections (1.5 μ L each) was added into the cell with 250 s injection intervals. The stir rate was 1000 rpm. All data were recorded with the GE Instruments software provided. Control experiments were conducted by titrating MOPS buffer into human telomeric G-quadruplex DNA and titrating CuLn into MOPS buffer under identical experimental condition to correct binding isotherm for background heat effects. Calorimetric data were further analyzed according to relevant model using MicroCal ORIGIN software and MATLAB. Data analysis gives Δ H (binding enthalpy change, kcal/mol), K_a (binding constant, M⁻¹), and n (number of bound CuLn cofactor) whereas the change in Gibbs energy and the entropic contribution were determined by the relationships Δ G = -RT lnK_a and Δ G= Δ H-T Δ S, respectively.

Dienophiles **1a-f**, **4a-e** and their corresponding racemic products were synthesized according to the literature.¹⁻⁵





a) Synthesis of ligands (L1-L4).⁶

4'-substituted benzaldehyde (I_b): 4-hydroxybenzaldehyde (2.2 g, 18 mmol) and corresponding chloride hydrochloride (27 mmol) were dissolved in 100 mL of dried-acetone. Then, anhydrous potassium carbonate (4.97 g, 36 mmol) and sodium iodide (0.68 g, 4.5 mmol) was added to the flask. The reaction was refluxed under dried N₂ for about 24 hs. The flask was cooled to RT. The suspension is filtered, and the filtrate was concentrated *in vacuo*. The obtained solid was redissolved in EtOAc. The organic layer was washed with brine, and dried with Na₂SO₄. The drying agent was removed by filtration and the filtrate was concentrated and dried *in vacuo* to give a thick and pale yellow oil. The unpurified oil was used without further purification.

4'-substituted-2,2':6',2''-terpyridine (Ln): 2.61 mL of 2-acetylpyridine (2.813 g, 23.2 mmol, 2 equiv) was added to a solution of 4'-substituted benzaldehyde (11.6 mmol, 1 equiv) in 50 mL of ethanol. Then, KOH pellets (2.6 g, 85%, 46.5 mmol, 4 equiv) were added to this solution. The reaction was stirred at RT for 10 min. Subsequently, 40 mL of 25% aq. NH₃ was added to the flask drop-wise. After 24 h of stirring at 34 °C, 5 mL of 25% aq. NH₃ was added to the reaction mixture again. The flask was cooled to -20 °C and then the obtained white precipitate is filtered and washed with cool ethanol. We further purified the ligand by a subsequent recrystallization from ethanol-H₂O. The ligand was recovered by filtration, washed with cold ethanol and petroleum ether, and dried under high vacuum for 24 h.



4'-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-2,2':6',2''-terpyridine L1 White flaky crystal. ¹**H NMR** (400 MHz, CDCl₃): δ (ppm) 8.75 – 8.69 (m, 4H), 8.66 (d, *J* = 8.0 Hz, 2H), 7.91 – 7.80 (m, 4H), 7.37 – 7.28 (m, 2H), 7.04 (d, *J* = 8.7 Hz, 2H), 4.18 (t, *J* = 5.9 Hz, 2H), 2.93 (t, *J* = 5.9 Hz, 2H), 2.70 – 2.57 (m, 4H), 1.89 – 1.74 (m, 4H). ¹³**C NMR** (101 MHz, CDCl₃): δ (ppm) 160.0, 156.5, 156.0, 149.9, 149.2, 136.9, 130.9, 128.6, 123.8, 121.5, 118.4, 115.1, 67.4, 55.2, 54.9, 23.7.



4'-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-2,2':6',2''-terpyridine (L2) White flaky crystal. ¹**H NMR** (400 MHz, CDCl₃): δ (ppm) 8.76 – 8.68 (m, 4H), 8.66 (d, *J* = 8.0 Hz, 2H), 7.91 – 7.81 (m, 4H), 7.37 – 7.29 (m, 2H), 7.03 (d, *J* = 8.7 Hz, 2H), 4.17 (t, *J* = 6.1 Hz, 2H), 2.80 (t, *J* = 6.1 Hz, 2H), 2.53 (t, 4H), 1.69 – 1.55 (m, 4H), 1.51 – 1.40 (m, 2H). ¹³**C NMR** (101 MHz, CDCl₃): δ (ppm) 159.9, 156.5, 155.9, 149.8, 149.2, 136.9, 130.8, 128.6, 123.8, 121.5, 118.4, 115.1, 66.3, 58.1, 55.2, 26.1, 24.3.



White needle-shaped crystal. ¹**H NMR** (400 MHz, CDCl₃): δ (ppm) 8.75 – 8.69 (m, 4H), 8.66 (d, *J* = 7.9 Hz, 2H), 7.91 – 7.81 (m, 4H), 7.37 – 7.30 (m, 2H), 7.03 (d, *J* = 8.7 Hz, 2H), 4.17 (t, *J* = 5.7 Hz, 2H), 3.78 – 3.72 (m, 4H), 2.83 (t, *J* = 5.7 Hz, 2H), 2.64 – 2.55 (m, 4H). ¹³**C NMR** (101 MHz, CDCl₃): δ (ppm) 159.8, 156.5, 156.0, 149.8, 149.2, 137.0, 131.0, 128.6, 123.9, 121.5, 118.4, 115.1, 67.1, 66.1, 57.8, 54.3.

2-(4-([2,2':6',2''-terpyridin]-4'-yl)phenoxy)-N,N-



L3

White needle-shaped crystal. ¹H NMR (400 MHz, CDCl₃): δ (ppm) 8.75 – 8.69 (m, 4H), 8.65 (d, J = 8.0 Hz, 2H), 7.91 – 7.81 (m, 4H), 7.36 – 7.29 (m, 2H), 7.04 (d, J = 8.6 Hz, 2H), 4.13 (td, J = 5.7, 0.8 Hz, 2H), 2.76 (t, J = 5.5 Hz, 2H), 2.36 (s, 6H). ¹³C NMR (101 MHz, CDCl₃): δ (ppm) 160.0, 156.6, 156.0, 149.9, 149.2, 137.0, 131.0, 128.6, 123.9, 121.5, 118.4, 115.1, 66.3, 58.5, 46.1.

b) Synthesis of metal complex CuLn ($n = 1 \sim 6$).⁷

 $4.8 \text{ mL of Cu(NO_3)_2} \bullet 3H_2O$ (48.3 mg, 0.2 mmol, 1.0 equiv.) in anhydrous acetonitrile is added to a solution of 4'-substituted-2,2':6',2''-terpyridine (0.2 mmol, 1.0 equiv.) in 4.8 mL of anhydrous DCM and the solution is put in the fridge for 3-4 days. The obtained precipitate is filtered, washed with cool ethanol and dried under high vacuum for 24 h.



CuL1 is obtained as green solid. **HRMS** (TOF ES⁺) calcd for $[C_{27}H_{26}ClN_4OCu]^+$: 520.1091, found: 520.1092.

CuL2 is obtained as green solid. **HRMS** (TOF ES⁺) calcd for $[C_{28}H_{28}ClN_4OCu]^+$: 534.1248, found: 534.1254.

CuL3 is obtained as green solid. **HRMS** (TOF ES⁺) calcd for $[C_{27}H_{26}ClN_4O_2Cu]^+$: 536.1040, found: 536.1049.

CuL4 is obtained as green solid. HRMS (TOF ES⁺) calcd for $[C_{25}H_{24}ClN_4OCu]^+$: 494.0935, found: 494.0938.

CuL5 is obtained as blue crystal. **HRMS** (TOF ES⁺) calcd for $[C_{22}H_{17}ClN_3Cu]^+$: 421.0407, found: 421.0410.

CuL6 is obtained as blue crystal. **HRMS** (TOF ES⁺) calcd for $[C_{15}H_{11}ClN_3OCu]^+$: 330.9938, found: 330.9942.



Supplementary Methods Note 3: General catalytic procedure

To a MOPS buffer (0.5 mL, 20 mM, pH 6.5) containing NaCl (50mM) or KCl (150 mM) or NH₄Cl (30 mM), an aqueous solution of human telomeric DNA (final G-quadruplex unit conc. 50 μ M) was added. After stirred for a half hour at 4 °C, a solution of Cu(Ln)(NO₃)₂ (final conc. 100 μ M) was added. Then, aza-chalcones **1** or **4** in CH₃CN (5 μ L of a 0.1 M solution, 1 mM) was added. The reaction was initiated by the addition of freshly distilled cyclopentadiene **2** (10 μ L, 260 mM) and the mixture was stirred for 24 hours at 4 °C, followed by the extraction with diethyl ether (3 × 5 mL), and the solvent was removed under reduced pressure. After a short flash chromatography, the residue was directly analyzed by ¹H-NMR and HPLC. The conversions were determined by ¹H-NMR and HPLC (only for **3a**) of the crude product.^{8,9} The diastereoselectivity (*endo/exo*) and enantiomeric excess (*ee*) were determined by chiral HPLC.

Supplementary Methods Note 4: HPLC analysis condition

Product **3a**: Daicel Chiralcel-ODH, *n*-hexane/*i*-PrOH 98:2, flow rate 0.5 mL/min, $\lambda = 212$ nm). Product **3b**: Daicel Chiralcel-ODH, *n*-hexane/*i*-PrOH 98:2, flow rate 0.5 mL/min, $\lambda = 212$ nm). Product **3c**: Daicel Chiralcel-OJH, *n*-hexane/*i*-PrOH 95:5, flow rate 1.0 mL/min, $\lambda = 212$ nm). Product **3d**: Daicel Chiralcel-OJH, *n*-hexane/*i*-PrOH 90:10, flow rate 0.5 mL/min, $\lambda = 212$ nm). Product **3e**: Daicel Chiralcel-OJH, *n*-hexane/*i*-PrOH 90:10, flow rate 0.5 mL/min, $\lambda = 254$ nm). Product **3f**: Daicel Chiralpak-ADH, *n*-hexane/*i*-PrOH 90:10, flow rate 1.0 mL/min, $\lambda = 254$ nm). Product **5a**: Daicel Chiralcel-OD, *n*-hexane/*i*-PrOH 99:1, flow rate 0.5 mL/min, $\lambda = 254$ nm). Product **5b**: Daicel Chiralpak-ADH, *n*-hexane/*i*-PrOH 97:3, flow rate 0.5 mL/min, $\lambda = 254$ nm). Product **5c**: Daicel Chiralpak-ADH, *n*-hexane/*i*-PrOH 97:3, flow rate 1.0 mL/min, $\lambda = 254$ nm). Product **5c**: Daicel Chiralpak-ADH, *n*-hexane/*i*-PrOH 98:2, flow rate 1.0 mL/min, $\lambda = 254$ nm). Product **5c**: Daicel Chiralpak-ADH, *n*-hexane/*i*-PrOH 97:3, flow rate 1.0 mL/min, $\lambda = 254$ nm). Product **5c**: Daicel Chiralpak-ADH, *n*-hexane/*i*-PrOH 98:2, flow rate 1.0 mL/min, $\lambda = 254$ nm). Product **5c**: Daicel Chiralpak-ADH, *n*-hexane/*i*-PrOH 97:3, flow rate 1.0 mL/min, $\lambda = 254$ nm).

Supplementary Methods Note 5: Calculation the conversion of 1a

The procedure to determine the conversion of **1a** by HPLC was according to the literature.^{8,9} Conversions of **1a** were calculated using the formula:

Conversion (%) = $A_{3a} / (A_{3a} + A_{Ia} / f)$

Where A_{Ia} and A_{3a} are the HPLC peak areas of **1a** and **3a**, respectively. And *f* is the correction factor determined to be 0.73 from a calibration curve.

Supplementary Methods Note 6: Kinetic measurements

All kinetic measurements were performed using UV-Vis spectroscopy (Shimadzu 2450) at 293 K by monitoring the disappearance of the absorption of **1a** at 326 nm. Typical procedure is described as follows: G4-DNA (final G-quadruplex unit conc. 25 μ M) was added to MOPS (20 mM, pH 6.5) containing NH4Cl (30 mM) in a quartz cuvette. After stirring for 15 min, CuL1 complex (final conc. 50 μ M) was added. After stirring for another 15 min, a series of concentration of [**1a**] equal to 20, 40, 60 and 80 μ M was added. The determination was made after **2** (final conc. 16 mM) was added with the cuvette sealed tightly. The D-A reaction was regarded as pseudo-first-order reaction as **2** is present in excess and **1a** is present at low concentrations. Enzymatic kinetic parameters (k_{cat} and K_M) were obtained by fitting the data to the Michaelis–Menten equation ($v_0 = k_{cat}[E_{catalyst}]_0[S_{1a}]_0/(K_M+[S_{1a}]_0))$. k_{cat}/K_M values were obtained by fitting the initial linear portion of the Michaelis–Menten plot to $v_0 = (k_{cat}/K_M)$ [$E_{catalyst}]_0[S_{1a}]_0$.

¹H and ¹³C NMR Spectra of Products

(3-phenylbicyclo[2.2.1]hept-5-en-2-yl)(pyridin-2-yl)methanone (3a)

¹H NMR (400 MHz, CDCl₃, *endo* isomer): δ 8.67 (m, 1H), 8.00 (m, 1H), 7.81 (m, 1H), 7.49 – 7.39 (m, 1H), 7.36 – 7.23 (m, 4H), 7.17 (m, 1H), 6.49 (m, 1H), 5.82 (m, 1H), 4.53 (m, 1H), 3.54 (s, 1H), 3.45 (d, *J* = 3.9 Hz, 1H), 3.09 (s, 1H), 2.07 (d, *J* = 8.4 Hz, 1H), 1.62 (m, 1H).



pyridin-2-yl(3-p-tolylbicyclo[2.2.1]hept-5-en-2-yl)methanone (**3b**)

¹H NMR (400 MHz, CDCl₃, *endo* isomer): δ 8.67 (d, *J* = 4.6 Hz, 1H), 8.00 (d, *J* = 7.8 Hz, 1H), 7.81 (td, *J* = 7.7, 1.3 Hz, 1H), 7.44 (dd, *J* = 7.0, 5.3 Hz, 1H), 7.21 (d, *J* = 8.0 Hz, 2H), 7.08 (d, *J* = 7.9 Hz, 2H), 6.49 (dd, *J* = 5.4, 3.3 Hz, 1H), 5.81 (dd, *J* = 5.6, 2.7 Hz, 1H), 4.52 (dd, *J* = 4.9, 3.7 Hz, 1H), 3.53 (s, 1H), 3.41 (d, *J* = 5.0 Hz, 1H), 3.05 (s, 1H), 2.30 (s, 3H), 2.06 (d, *J* = 8.4 Hz, 1H), 1.59 (dd, *J* = 8.5, 1.1 Hz, 1H).



(3-(4-methoxyphenyl)bicyclo[2.2.1]hept-5-en-2-yl)(pyridin-2-yl)methanone (3c)

¹H NMR (400 MHz, CDCl₃, *endo* isomer): δ 8.74 – 8.60 (m, 1H), 8.00 (d, *J* = 7.9 Hz, 1H), 7.81 (td, *J* = 7.7, 1.7 Hz, 1H), 7.44 (ddd, *J* = 7.5, 4.8, 1.1 Hz, 1H), 7.28 – 7.18 (m, 2H), 6.86 – 6.78 (m, 2H), 6.48 (dd, *J* = 5.5, 3.2 Hz, 1H), 5.81 (dd, *J* = 5.6, 2.7 Hz, 1H), 4.49 (dd, *J* = 5.1, 3.5 Hz, 1H), 3.77 (s, 3H), 3.53 (s, 1H), 3.39 (d, *J* = 4.5 Hz, 1H), 3.02 (d, *J* = 1.2 Hz, 1H), 2.06 (d, *J* = 8.4 Hz, 1H), 1.60 (dd, *J* = 8.5, 1.6 Hz, 1H).



(3-(4-chlorophenyl)bicyclo[2.2.1]hept-5-en-2-yl)(pyridin-2-yl)methanone (3d)

¹H NMR (400 MHz, CDCl₃, *endo* isomer): δ 8.67 (d, *J* = 4.6 Hz, 1H), 8.00 (d, *J* = 7.8 Hz, 1H), 7.83 (dd, *J* = 8.5, 6.9 Hz, 1H), 7.46 (dd, *J* = 7.4, 4.9 Hz, 1H), 7.25 – 7.10 (m, 4H), 6.48 (dd, *J* = 5.4, 3.2 Hz, 1H), 5.83 (dd, *J* = 5.5, 2.7 Hz, 1H), 4.46 (dd, *J* = 5.1, 3.5 Hz, 1H), 3.54 (s, 1H), 3.40 (d, *J* = 5.1 Hz, 1H), 3.05 (s, 1H), 2.01 (d, *J* = 8.5 Hz, 1H), 1.62 (d, *J* = 8.6 Hz, 1H).



(3-(4-nitrophenyl)bicyclo[2.2.1]hept-5-en-2-yl)(pyridin-2-yl)methanone (3e)

¹H NMR (400 MHz, *endo* isomer): δ 8.66 (d, *J* = 4.5 Hz, 1H), 8.07 (m, 3H), 7.84 (t, *J* = 7.6 Hz, 1H), 7.47 (m, 3H), 6.52 – 6.44 (m, 1H), 5.88 (dd, *J* = 5.3, 2.5 Hz, 1H), 4.51 – 4.44 (m, 1H), 3.66 – 3.50 (m, 2H), 3.13 (s, 1H), 2.00 (d, *J* = 8.6 Hz, 1H), 1.67 (d, *J* = 8.4 Hz, 1H).



(3-(naphthalen-1-yl)bicyclo[2.2.1]hept-5-en-2-yl)(pyridin-2-yl)methanone (3f)

¹H NMR (400 MHz, CDCl₃, *endo* isomer): δ 8.70 – 8.57 (m, 1H), 8.18 – 7.98 (m, 2H), 7.87 – 7.76 (m, 2H), 7.70 (d, *J* = 8.2 Hz, 1H), 7.62 (d, *J* = 7.2 Hz, 1H), 7.49 – 7.37 (m, 4H), 6.68 – 6.57 (m, 1H), 5.97 – 5.89 (m, 1H), 4.74 – 4.65 (m, 1H), 4.07 (d, *J* = 4.8 Hz, 1H), 3.53 (s, 1H), 3.21 (s, 1H), 2.19 (dd, *J* = 8.4 Hz, 1H), 1.69 (dd, *J* = 8.3 Hz, 1H).



(1-methyl-1H-imidazol-2-yl)(3-phenylbicyclo[2.2.1]hept-5-en-2-yl)methanone (5a)

¹H NMR (400 MHz, CDCl₃, *endo* isomer): δ 7.26 – 7.15 (m, 4H), 7.11 – 7.03 (m, 2H), 6.93 (s, 1H), 6.44 (dd, *J* = 5.0, 3.4 Hz, 1H), 5.82 (dd, *J* = 5.4, 2.6 Hz, 1H), 4.35 – 4.26 (m, 1H), 3.89 (s, 3H), 3.53 (s, 1H), 3.28 (d, *J* = 5.1 Hz, 1H), 2.97 (s, 1H), 1.96 (d, *J* = 8.5 Hz, 1H), 1.52 (d, *J* = 8.5 Hz, 1H).



(1-methyl-1H-imidazol-2-yl)(3-p-tolylbicyclo[2.2.1]hept-5-en-2-yl)methanone (5b)

¹H NMR (400 MHz, CDCl₃) *endo* isomer: $\delta = 7.21$ (d, J=7.8, 2H), 7.17 – 7.05 (m, 2H), 7.05 – 6.97 (m, 2H), 6.55 – 6.45 (m, 1H), 5.89 (dd, J=5.3, 2.4, 1H), 4.42 – 4.34 (m, 1H), 3.95 (s, 3H), 3.60 (s, 1H), 3.32 (d, J=5.0, 1H), 3.00 (s, 1H), 2.29 (s, 3H), 2.04 (d, J=8.4, 1H), 1.58 (d, J=8.5, 1H). *exo isomer*: $\delta = 7.17 - 7.05$ (m, 5H), 7.05 – 6.97 (m, 1H), 6.55 – 6.45 (m, 1H), 6.11 – 6.04 (m, 1H), 4.42 – 4.34 (m, 1H), 3.99 (m, 4H), 3.16 (m, 2H), 2.27 (s, 3H), 2.04 (d, J=8.4, 1H), 1.46 (d, J=8.5, 1H).



(3-(4-methoxyphenyl)bicyclo[2.2.1]hept-5-en-2-yl)(1-methyl-1H-imidazol-2-yl)methanone (**5c**) ¹H NMR (400 MHz, CDCl₃, *endo* isomer): δ 7.15 (d, *J* = 8.6 Hz, 2H), 7.07 (s, 1H), 6.92 (s, 1H), 6.74 (d, *J* = 8.7 Hz, 2H), 6.42 (dd, *J* = 5.5, 3.2 Hz, 1H), 5.81 (dd, *J* = 5.6, 2.7 Hz, 1H), 4.27 (dd, *J* = 5.2, 3.5 Hz, 1H), 3.89 (s, 3H), 3.69 (s, 3H), 3.51 (s, 1H), 3.22 (d, *J* = 4.8 Hz, 1H), 2.91 (s, 1H), 1.95 (d, *J* = 8.5 Hz, 1H), 1.51 (dd, *J* = 8.6, 1.5 Hz, 1H).



(3-(4-chlorophenyl)bicyclo[2.2.1]hept-5-en-2-yl)(1-methyl-1H-imidazol-2-yl)methanone (**5d**) ¹H NMR (400 MHz, CDCl₃, *endo* isomer): δ 7.20 – 7.05 (m, 5H), 6.94 (s, 1H), 6.42 (dd, *J* = 5.6, 3.2 Hz, 1H), 5.82 (dd, *J* = 5.6, 2.8 Hz, 1H), 4.23 (dd, *J* = 5.2, 3.5 Hz, 1H), 3.88 (d, *J* = 7.8 Hz, 3H), 3.53 (s, 1H), 3.24 (dd, *J* = 5.3, 1.6 Hz, 1H), 2.93 (d, *J* = 1.3 Hz, 1H), 1.90 (d, *J* = 8.6 Hz, 1H), 1.53 (dd, *J* = 8.6, 1.6 Hz, 1H).



(3-(4-bromophenyl)bicyclo[2.2.1]hept-5-en-2-yl)(1-methyl-1H-imidazol-2-yl)methanone (**5e**) ¹H NMR (400 MHz, CDCl₃, *endo* isomer): δ 7.43 – 7.29 (m, 2H), 7.21 – 7.05 (m, 3H), 7.01 (s, 1H), 6.58 – 6.39 (m, 1H), 5.90 (dd, *J* = 5.3, 2.5 Hz, 1H), 4.42 – 4.25 (m, 1H), 3.96 (s, 3H), 3.61 (s, 1H), 3.30 (d, *J* = 5.1 Hz, 1H), 3.00 (s, 1H), 1.97 (d, *J* = 8.6 Hz, 1H), 1.60 (d, *J* = 8.5 Hz, 1H).



 $\begin{array}{c} \underbrace{+19}{4.18} \\ \underbrace{+4.19}{4.16} \\ \underbrace{+2.95}{2.295} \\ \underbrace{+2.92}{2.263} \\ \underbrace{+1.81}{2.63} \\ \underbrace{+1.81}{1.80} \\ \underbrace{+1.81}{1.80} \end{array}$ \mathbb{N} N Ì N.∕∕ __N L1 4.02-I 2.01⊣ 2.01⊣ 2.01-I 2.00-f 4.02-f 4.03H $^{3.96}_{2.00}$ ¥ 11.5 11.0 10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 f1 (ppm) 3.0 2.5 2.0 1.5 1.0 0.5 0.0 ^{160.0}
 ^{160.0}
 ^{156.5}
 ^{156.5}
 ^{156.6}
 ^{126.0}
 ^{126.9}
 ^{123.8}
 ^{123.8}
 ^{123.8}
 ^{113.1}
 ^{115.1} -67.4< 55.2< 54.9-23.7 .N. N __N L1 220 210 200 190 180 170 160 150 140 130 120 110 100 90 f1 (ppm) 0 70 30 20 10 80 60 50 40







HPLC Traces of Products

1. Product 3a

(1) Racemic 3a

Retention times: 13.0, 14.7 (exo isomer) and 17.0, 22.0 (endo isomer) mins



*** End of Report ***

(2) Product **3a** from the Diels-Alder reaction catalyzed by HT21-NH4-CuL1 (*endo* isomer:



94% ee)

面积百分比报告

排序	:	信号
乘积因子	:	1.0000
稀释因子	:	1.0000
内标使用乘积因子和	稀释因子	

信号 1: VWD1 A, Wavelength=212 nm

峰	保留时间	类型	峰宽	峰面积		峰面积 峰高		峰面积
#	[min]		[min]	mAU	*s	[mAU]	음
1	13.060	VV	0.3693	257.	80942	10.3	34860	1.3184
2	14.657	VV	0.4261	175.	22066	5.8	30997	0.8961
3	16.711	VB	0.4314	1.854	128e4	645.1	9928	94.8286
4	21.923	BB	0.4650	578.	18036	19.1	1723	2.9568

(3) Product 3a from the Diels-Alder reaction catalyzed by L-HT21-NH4-CuL1 (endo isomer:



-92% ee)

2. Product 3b

(1) Racemic **3b**

Retention times: 11.0, 12.6 (exo isomer) and 13.4, 18.1 (endo isomer) mins



*** End of Report ***

(2) Product 3b from the Diels-Alder reaction catalyzed by HT21-NH4-CuL1 (endo isomer:



2.4525

96% ee)

总量: 2.39658e4 1179.27069

4 18.497 VB 0.3937 587.75977 22.82935

3. Product **3c**

(1) Racemic 3c

Retention times: 13.8, 14.2 (exo isomer) and 16.6, 22.8 (endo isomer) mins

VWD1 A, Wavelength	=212 nm (LYH130929\DEF_LC 2013	-09-15 20-19-07\001-0101.D)	
VWD1 A, Wavelength mAU = 350 = 300 = 250 = 150 = 100 = 0 = 0 =	=212 nm (LYH130929\DEF_LC 2013	-09-15 20-19-07/001-0101.D)	22.808
0	5 1	0 15	20 min
Sorted By Multiplier: Dilution: Use Multiplier & Dilu Signal 1: VWD1 A, Wav	Area Percent Report : Signal : 1.0000 : 1.0000 ution Factor with ISTDs relength=212 nm)) 5	
Peak RetTime Type Wi # [min] [n	idth Area Heig nin] [mAU*s] [mAU	ht Area J] %	
1 13.807 BV 0. 2 14.187 VB 0. 3 16.611 VB 0. 4 22.808 BB 0.	2309 708.48175 47.1 2528 748.52386 45.2 3120 7994.28027 399.8 4420 8170.07568 287.8	0786 4.0206 4762 4.2478 87192 45.3670 92578 46.3646	
Totals :	1.76214e4 780.0	05318	

*** End of Report ***

(2) Product 3c from the Diels-Alder reaction catalyzed by HT21-NH4-CuL1 (endo isomer:



98% ee)

4. Product 3d

(1) Racemic **3d**

Retention times: 20.8, 26.9 (exo isomer) and 25.4, 44.4 (endo isomer) mins

VWD1 A, Wavelength=212 n	m (LYH130929\DEF_LC 2013-09-1	6 08-47-17\001-0101.D)	
mAU = 350 = 250 = 150 = 100 = 50 = 0 =	26.875 26.864	44.427	
0 10	20 30 4	40 50 60	70 80 min
Sorted By : Multiplier: Dilution: Use Multiplier & Dilution Signal 1: VWD1 A, Wavelen	Area Percent Report Signal : 1.0000 : 1.0000 Factor with ISTDs		
Peak RetTime Type Width # [min] [min] 1 20.820 BB 0.5783 2 25.364 VV 0.6586 3 26 875 VB 0.8004	Area Height [mAU*s] [mAU] 	Area % 	
4 44.427 BB 1.3103	1.77327e4 206.026	75 46.0196	
Totals :	3.85330e4 693.099	89	

*** End of Report ***

(2) Product 3d from the Diels-Alder reaction catalyzed by HT21-NH4-CuL1 (endo isomer:

mAU : 600

93% ee)



5. Product 3e

(1) Racemic 3e

Retention times: 12.5, 16.0 (exo isomer) and 14.6, 18.1 (endo isomer) mins



*** End of Report ***

(2) Product 3e from the Diels-Alder reaction catalyzed by HT21-NH4-CuL1 (endo isomer:

99% ee)



6. Product 3f

(1) Racemic 3f

Retention times: 7.4 and 10.8 mins



*** End of Report ***

(2) Product **3f** from the Diels-Alder reaction catalyzed by HT21-NH4-CuL1 (*endo* isomer:

VWD1 A, Wavelength=254 nm (8-99(LYH140711)(1260)\DEF_LC140510 2014-07-11 20-51-00\035-0101.D) mAU] 400 -350 -300 -250 -200 -81274 (1019): 60.5295 150 -100 -50 -0 12 10 14 面积百分比报告 _____ _____ 排序 信号 : · 乘积因子 : 稀释因子 1.0000 1.0000 内标使用乘积因子和稀释因子 信号 1: VWD1 A, Wavelength=254 nm 峰面积 峰 保留时间 类型 峰宽 峰面积 峰高 # [min] [mAU*s] [mAU] do 1 7.278 MM 0.1379 60.52946 7.31544 1.0320 2 10.313 VB 0.1985 5804.98926 450.19852 98.9680 总量 : 5865.51872 457.51395

98% ee)

7. Product 5a

(1) Racemic 5a

Retention times: 21.9, 27.1 (exo isomer) and 25.1, 35.1 (endo isomer) mins



(2) Product 5a from the Diels-Alder reaction catalyzed by HT21-NH4-CuL1 (endo isomer:

98% ee)



8. Product 5b

(1) Racemic 5b

Retention times: 30.0, 35.5 (exo isomer) and 37.5, 40.3 (endo isomer) mins



(2) Product **5b** from the Diels-Alder reaction catalyzed by HT21-NH4-CuL1 (endo isomer:

VWD1 A, Wavelength=254 nm (8-100\LYH140714\DEF_LC 2014-07-15 11-15-01\052-0201.D) 100 HI. 6504.83 mAU 80 -60 -40 -20 40.944 30.195 965 5 0 35 15 20 30 40 45 10 25 面积百分比报告 排序 : 信号 乘积因子 1.0000 : 稀释因子 1.0000 . 内标使用乘积因子和稀释因子 信号 1: VWD1 A, Wavelength=254 nm 峰 保留时间 类型 峰宽 峰面积 峰面积 峰高 # [min] [min] mAU *s [mAU] 8 _____ 1 30.195 BV 0.5047 107.16024 3.32005 1.5619
 1
 30.135
 BV
 0.5047
 10.18024
 5.52005
 1.5019

 2
 35.965
 MF
 0.8175
 42.98543
 8.76339e-1
 0.6265

 3
 37.810
 FM
 1.1464
 6504.83301
 94.57201
 94.8076

 4
 40.944
 BB
 0.5524
 206.10716
 5.76660
 3.0040
 总量 : 6861.08584 104.53500

94% ee)

9. Product 5c

(1) Racemic 5c

Retention times: 14.4, 21.6 (exo isomer) and 17.4, 28.0 (endo isomer) mins



(2) Product 5c from the Diels-Alder reaction catalyzed by HT21-NH4-CuL1 (endo isomer:

VWD1 A, Wavelength=254 nm (8-100\LYH140714\DEF_LC 2014-07-15 16-10-51\053-0201.D) mAU 50 · 40 -30 -20 -2 10 -14.304 0 30 10 1520 25 35 面积百分比报告 _____ _____ 排序 信号 : 乘积因子 : 1.0000 稀释因子 1.0000 : 内标使用乘积因子和稀释因子 信号 1: VWD1 A, Wavelength=254 nm 峰 保留时间 类型 峰宽 峰面积 峰高 峰面积 # [min] [min] mAU *s [mAU] do 1 14.304 MF 0.4429 19.14496 7.20490e-1 1.0755 2 17.312 BB 0.5007 1760.96838 53.26444 98.9245 总量 : 1780.11334 53.98493

>99% ee)

10. Product **5d**

(1) Racemic 5d

Retention times: 6.4, 9.9 (exo isomer) and 6.8, 8.8 (endo isomer) mins



(2) Product **5d** from the Diels-Alder reaction catalyzed by HT21-NH4-CuL1 (*endo* isomer:

VWD1 A, Wavel	ength=254 nm (8	-100\LYH140714	-DEF_LC 2014-07) ال	15 21-09-39\054-	0201.D)		
			1				
300 -							
000							
250 -							
200 -							
150							
100							
50 -			438		26		
					8		
°] 		· · · · ·		· · · . ·			· · 1
0	2	4	6	8	10	12	14
		面积百	分比报告				
序		信号					
[2] [2] [2] [2] [2] [2] [2] [2] [2] [2]		1.0000					
释因子		1.0000					
1标使用乘积因子利	口稀释因子						
言号 1: VWD1 A, W	avelength=	254 nm					
	नेत्र योग	14 15 AC	the star	14 75 10			
峰 保留时间 类型	峰苋	峰田枳	峰尚	峰田枳			
# [min]	[min] m	IAU *s	[mau]	8			
1 6 438 577	0 1/07	1/6 81802	15 11268	3 5020			
2 6.786 VR	0.1726 4	001.93457	354,20807	95.4564			
3 8.997 BB	0.2415	43.66702	2.80290	1.0416			
3量 :	4	192.42052	372.12365				

98% ee)

11. Product 5e

(1) Racemic 5e

Retention times: 15.6, 31.0 (exo isomer) and 17.6, 36.1 (endo isomer) mins



*** End of Report ***

(2) Product 5e from the Diels-Alder reaction catalyzed by HT21-NH4-CuL1 (endo isomer:

>99% ee)



References

1	S. Otto, F. Bertoncin and J. B. F. N. Engberts, J. Am. Chem. Soc., 1996, 118, 7702.
2	D. A. Evans, K. R. Fandrick and HJ. Song, J. Am. Chem. Soc., 2005, 127, 8942.
3	M. C. Myers, A. R. Bharadwaj, B. C. Milgram and K. A. Scheidt, J. Am. Chem. Soc.,
	2005, 127 , 14675.
4	G. Roelfes, A. J. Boersma and B. L. Feringa, Chem. Commun., 2006, 635.
5	L. Wang, J. Zhang, N. Wang, X. Yang, Q. Wang and X. Yu, Lett. Org. Chem., 2009, 6,
	392.
6	C. Wei, L. Ren and N. Gao, Int. J. Biol. Macromol., 2013, 57, 1.
7	H. Bertrand, D. Monchaud, A. De Cian, R. Guillot, JL. Mergny and MP. Teulade-
	Fichou, Org. Biomol. Chem., 2007, 5, 2555.
8	N. S. Oltra and G. Roelfes, Chem. Commun., 2008, 6039.
9	C. H. Wang, G. Q. Jia, J. Zhou, Y. H. Li, Y. Liu, S. M. Lu and C. Li, Angew. Chem. Int.
	<i>Ed.</i> , 2012, 51 , 9352.